Bausch & Lomb Incorporated - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 72

Bausch & Lomb Incorporated – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Bausch & Lomb Incorporated - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Bausch & Lomb Incorporated - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Bausch & Lomb Incorporated human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Bausch & Lomb Incorporated with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Bausch & Lomb Incorporated’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Bausch & Lomb Incorporated’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Bausch & Lomb Incorporated in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Bausch & Lomb Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Bausch & Lomb Incorporated.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Bausch & Lomb Incorporated and identify potential opportunities in those areas.

List of Tables
List of Figures
Bausch & Lomb Incorporated Snapshot
Bausch & Lomb Incorporated Overview
Key Information
Key Facts
Bausch & Lomb Incorporated – Research and Development Overview
Key Therapeutic Areas
Bausch & Lomb Incorporated – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Bausch & Lomb Incorporated – Pipeline Products Glance
Bausch & Lomb Incorporated – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Bausch & Lomb Incorporated Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Bausch & Lomb Incorporated – Drug Profiles
Ketotifen/Naphazoline
Product Description
Mechanism of Action
R&D Progress
Loteprednol Etabonate + Tobramycin
Product Description
Mechanism of Action
R&D Progress
Mapracorat
Product Description
Mechanism of Action
R&D Progress
Mapracorat
Product Description
Mechanism of Action
R&D Progress
NCX-116
Product Description
Mechanism of Action
R&D Progress
Bausch & Lomb Incorporated – Pipeline Analysis
Bausch & Lomb Incorporated – Pipeline Products by Therapeutic Class
Bausch & Lomb Incorporated Pipeline Products By Target
Bausch & Lomb Incorporated – Pipeline Products by Route of Administration
Bausch & Lomb Incorporated – Pipeline Products by Molecule Type
Bausch & Lomb Incorporated – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Bausch & Lomb Incorporated - Key Manufacturing Facilities
Recent Developments
May 04, 2010: Bausch + Lomb Launches New Soothe Xtra Hydration Dry Eye Therapy Lubricant Eye Drops
Apr 09, 2010: Bausch + Lomb Launches New PreserVision Eye Vitamin And Mineral Supplement In US
Jun 22, 2009: Bausch & Lomb Canada Introduces Lotemax and Alrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
Jun 22, 2009: Bausch & Lomb Canada Introduces PrLotemax and PrAlrex
May 29, 2009: Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis (“Pink Eye”)
Financial Deals Landscape
Bausch & Lomb Incorporated, Deals Summary, 2004 to 2010
Bausch & Lomb Incorporated Detailed Deal Summary
Asset Purchase
Bausch & Lomb Acquires Ophthalmic Pharmaceuticals Portfolio From Tubilux Pharma
Bausch & Lomb Acquires Soothe Emollient (Lubricant) Eye Drops From Alimera Sciences
Bausch & Lomb Acquires Alimera’s OTC Eye Care Product
Acquisition
Bausch & Lomb Acquires eyeonics
AcuFocus Receives Investment From Bausch & Lomb
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical From Sino Biopharmaceutical
Private Equity
New York State Common Retirement Fund Invests $15 Million In Bausch & Lomb
Warburg Pincus Acquires Bausch & Lomb
Venture Financing
AcuFocus Secures $18 Million In Series D Financing
eyeonics Secures $16.5 Million In Fourth Round Of Financing
eyeonics Secures $16.2 million In Series E Preferred Stock Financing
Equity Offering
eyeonics Withdraws Its Initial Public Offering Of $86.25 Million
Bausch & Lomb Enters Into Agreement With Croma-Pharma
Bausch & Lomb Signs Joint Venture Agreement With 20/10 PERFECT VISION
Bausch & Lomb Enters Into Agreement With Santen Pharmaceutical
Pfizer Enters Into Co-Promotion Agreement With Bausch & Lomb
Advanced Medical Optics Enters Into Licensing Agreement With Bausch & Lomb
Bausch & Lomb Enters Into An Agreement With CrystalGenomics
Bausch & Lomb Enters Into Co-Promotion Agreement With Novartis Ophthalmics
Norwood EyeCare Signs An Agreement With Bausch & Lomb
CIBA Vision And Bausch & Lomb Enters Into Cross-License Agreement
Licensing Agreements
Bausch & Lomb Enters Into An Agreement With Galapagos
Bausch & Lomb Enters Into A Licensing Agreement With Schering
Bausch & Lomb Enters Into Licensing Agreement With Talecris Biotherapeutics
Bausch & Lomb Enters Into Licensing Agreement With Bayer HealthCare
Bausch & Lomb Enters Into Licensing Agreement With Cephalon
Bausch & Lomb Signs An Agreement With PTC Therapeutics
Psivida Enters Into Licensing Agrement With Bausch & Lomb
Bausch & Lomb Enters Into Licensing Agreement With Bayer HealthCare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Defense Robotics - Global Strategic Business Report
• Private Tutoring - Global Strategic Business Report
• The Global UAV Payload Market 2012-2022